The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Gagliani, N., Magnani, C. F., Huber, S., Gianolini, M. E., Pala, M., Licona-Limon, P., Guo, B., Herbert, D. R., Bulfone, A., Trentini, F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3179 · Cited by 793
Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Butler, N. S., Moebius, J., Pewe, L. L., Traore, B., Doumbo, O. K., Tygrett, L. T., Waldschmidt, T. J., Crompton, P. D., & Harty, J. T. (2012) · Nature Immunology · doi:10.1038/ni.2180 · Cited by 482
Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv276 · Cited by 464
Self-citationSchalper, K. A., Velcheti, V., Carvajal, D., Wimberly, H., Brown, J., Pusztai, L., & Rimm, D. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2702 · Cited by 450
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1510353 · Cited by 426
Baixeras, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., & Piatier-Tonneau, D. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.2.327 · Cited by 397
Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391
Workman, C. J., Cauley, L. S., Kim, I.-J., Blackman, M. A., Woodland, D. L., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5450 · Cited by 351
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Okazaki, T., Okazaki, I.-M., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 324
LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
Workman, C. J., Wang, Y., El Kasmi, K. C., Pardoll, D. M., Murray, P. J., Drake, C. G., & Vignali, D. A. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800185 · Cited by 316
Lung cancer incidence and mortality in China, 2009
Chen, W., Zheng, R., Zhang, S., Zou, X., Zhao, P., & He, J. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12025 · Cited by 309
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Grosso, J. F., Goldberg, M. V., Getnet, D., Bruno, T. C., Yen, H.-R., Pyle, K. J., Hipkiss, E., Vignali, D. A. A., Pardoll, D. M., & Drake, C. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804211 · Cited by 272
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
Kisielow, M., Kisielow, J., Capoferri-Sollami, G., & Karjalainen, K. (2005) · European Journal of Immunology · doi:10.1002/eji.200526090 · Cited by 271
Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R. (2006) · Blood · doi:10.1182/blood-2006-04-015164 · Cited by 255 · cited 1×
“Studies indicate that LAG-3 could suppress anticancer immunity in Hodgkin’s lymphoma.(65) It was reported that anti–LAG-3 therapy might control breast cancer in a mouse model.”
BackgroundMHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Hemon, P., Jean-Louis, F., Ramgolam, K., Brignone, C., Viguier, M., Bachelez, H., Triebel, F., Charron, D., Aoudjit, F., Al-Daccak, R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002050 · Cited by 252
CD3/TCR complex‐associated lymphocyte activation gene‐3 molecules inhibit CD3/TCR signaling
Hannier, S., Tournier, M., Bismuth, G., & Triebel, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4058 · Cited by 248
Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study
Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J. A., Janne, P., Oulid-Aissa, D., & Soria, J.-C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0260 · Cited by 201
Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)
Andreae, S., Piras, F., Burdin, N., & Triebel, F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3874 · Cited by 187
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
He, Y., Rivard, C. J., Rozeboom, L., Yu, H., Ellison, K., Kowalewski, A., Zhou, C., & Hirsch, F. R. (2016) · Cancer Science · doi:10.1111/cas.12986 · Cited by 185
Self-citationCutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
Bettini, M., Szymczak-Workman, A. L., Forbes, K., Castellaw, A. H., Selby, M., Pan, X., Drake, C. G., Korman, A. J., & Vignali, D. A. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100714 · Cited by 169
Li, F., Zhang, Y., Jin, G., Yao, L., & Wu, D. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.12.004 · Cited by 147
On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection
Richter, K., Agnellini, P., & Oxenius, A. (2009) · International Immunology · doi:10.1093/intimm/dxp107 · Cited by 141
Huard, B., Prigent, P., Pagès, F., Bruniquel, D., & Triebel, F. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260533 · Cited by 132
Lung cancer incidence and mortality in C hina, 2011
Zheng, R., Zeng, H., Zuo, T., Zhang, S., Qiao, Y., Zhou, Q., & Chen, W. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12286 · Cited by 119
Demeure, C. E., Wolfers, J., Martin‐Garcia, N., Gaulard, P., & Triebel, F. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00184-8 · Cited by 104
Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses
Prigent, P., mir, S. E., Dréano, M., & Triebel, F. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199912)29:12<3867::aid-immu3867>3.0.co;2-e · Cited by 97
Sakihama, T., Smolyar, A., & Reinherz, E. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6444 · Cited by 91
Cappello, P., Triebel, F., Iezzi, M., Caorsi, C., Quaglino, E., Lollini, P., Amici, A. R. D., Carlo, E. D., Musiani, P., Giovarelli, M., et al. (2003) · PubMed · Cited by 89
Walker, E., Haley, D. P., Miller, W. L., Floyd, K., Wisner, K. P., Sanjuan, N., Maecker, H. T., Romero, P. J., Hu, H., Alvord, W. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0095-03 · Cited by 79
Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity
Casati, C., Camisaschi, C., Rini, F., Arienti, F., Rivoltini, L., Triebel, F., Parmiani, G., & Castelli, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2728 · Cited by 72
Hannier, S., & Triebel, F. (1999) · International Immunology · doi:10.1093/intimm/11.11.1745 · Cited by 72
Squiring immunotherapy to CheckMate
Hutchinson, L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.110 · Cited by 63
髙屋, 誠. (2015) · Tottori University research result repository (Tottori University) · Cited by 62
Fougeray, S., Brignone, C., & Triebel, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.03.050 · Cited by 53
Lucas, C. L., Workman, C. J., Beyaz, S., LoCascio, S. A., Zhao, G., Vignali, D. A. A., & Sykes, M. (2011) · Blood · doi:10.1182/blood-2010-11-318675 · Cited by 46
Genomic organization of the human LAG-3/CD4 locus
Bruniquel, D., Borie, N., & Triebel, F. (1997) · Immunogenetics · doi:10.1007/s002510050332 · Cited by 44
Carlo, E. D., Cappello, P., Sorrentino, C., D’Antuono, T., Pellicciotta, A., Giovarelli, M., Forni, G., Musiani, P., & Triebel, F. (2004) · The Journal of Pathology · doi:10.1002/path.1679 · Cited by 44
HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer
Martin, M. P., Borecki, I. B., Zhang, Z., Nguyen, L., Ma, D., Gao, X., Qi, Y., Carrington, M. N., & Rader, J. S. (2010) · Immunogenetics · doi:10.1007/s00251-010-0477-5 · Cited by 37
New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer
Cameron, L., & Solomon, B. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0367-z · Cited by 31
He, Y., Li, S., Ren, S., Cai, W., Li, X., Zhao, C., Li, J., Chen, X., Gao, G., Li, W., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.004 · Cited by 31
Self-citationHe, Y., Wang, Y., Boyle, T. A., Ren, S., Chan, D., Rivard, C. J., Li, X., Li, J., Zhou, C., & Hirsch, F. R. (2016) · Medical Science Monitor · doi:10.12659/msm.896607 · Cited by 20
Self-citationCheckMate 067—frontline nivolumab improves PFS alone or in combination with ipilimumab
Errico, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.112 · Cited by 19
Correction: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival
Thoma, C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.207 · Cited by 6
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
LAG-3: from molecular functions to clinical applications
Maruhashi, T., Sugiura, D., Okazaki, I.-M., & Okazaki, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001014 · Cited by 459
Xia, L., Liu, Y., & Wang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s05 · Cited by 394
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 391
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
Metadata
- Authors
- He, Y., Yu, H., Rozeboom, L., Rivard, C. J., Ellison, K., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., Zhou, C., & Hirsch, F. R.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 12
- Issue
- 5
- Pages
- 814-823
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2569464488
- Cited by
- 268
- References
- 72
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.